SCHEMBL4367667

SCHEMBL4367667

O=c1ccc(Cc2ccc(Cl)c(Oc3ccccc3)c2)n[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.53
DAO P14920 1/20 0.37
TTR P02766 1/20 0.36
HPGD P15428 1/20 0.36
MAPK8 P45983 2/20 0.35
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35
KDM1A O60341 1/20 0.34
SMOX Q9NWM0 1/20 0.34
RCOR1 Q9UKL0 1/20 0.34
AKR1B1 P15121 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
TSHR P16473 1/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
KMT2A Q03164 1/20 0.34
P2RX3 P56373 1/20 0.34
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5373613 0.90 CYP3A4 (0.51) CYP3A4DAOTHRATHRBAKR1B1
SCHEMBL5365181 0.90 CYP3A4 (0.67) CYP3A4MAPK8AKR1B1
SCHEMBL5374337 0.89 CYP3A4 (0.47) CYP3A4AKR1B1CYP2C9CYP2C19TSHR
SCHEMBL5366918 0.88 CYP3A4 (0.47) CYP3A4THRATHRBAKR1B1KMT2A
SCHEMBL5368714 0.88 CYP3A4 (0.53) CYP3A4DAOTHRATHRBAKR1B1
SCHEMBL5377385 0.88 CYP3A4 (0.54) CYP3A4THRATHRBAKR1B1CYP2C9
SCHEMBL5385700 0.88 CYP3A4 (0.54) CYP3A4DAOTHRATHRB
SCHEMBL5364926 0.88 CYP3A4 (0.54) CYP3A4THRATHRBMEN1KMT2A
SCHEMBL5376942 0.88 CYP3A4 (0.54) CYP3A4CYP2C9CYP2C19TSHRMEN1
SCHEMBL5381986 0.86 CYP3A4 (0.47) CYP3A4DAOTHRATHRBAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625897-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2009-12-01 US disclosed
US-7625897-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2009-12-01 US disclosed
US-7625897-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2009-12-01 US disclosed
EP-1937651-B1 NNRT INHIBITORS HOFFMANN LA ROCHE (CH) 2008-12-24 EP disclosed
EP-1937651-B1 NNRT INHIBITORS HOFFMANN LA ROCHE (CH) 2008-12-24 EP disclosed
EP-1937651-A1 NNRT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2008-07-02 EP disclosed
WO-2007039463-A1 NNRT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO disclosed
WO-2007039463-A1 NNRT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO disclosed
US-20070078128-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-05 US disclosed
US-20070078128-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-05 US disclosed
US-20070078128-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-05 US disclosed
US-7189718-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-03-13 US disclosed
US-7189718-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-03-13 US disclosed
US-7189718-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078128-A1 Non-nucleoside reverse transcriptase inhibitors SAMHD1, HPRT1, RTF1 CYP3A4 350/4885DAO 919/4885TTR 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.